Treace Medical Concepts, Inc. (TMCI) - 2025 Annual Report Summary
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2025. Treace Medical Concepts is a medical technology company focused on surgical management of bunion and midfoot deformities. The company's flagship product is the Lapiplasty 3D Bunion Correction System. In 2025, the company expanded its portfolio with the full commercial release of minimally invasive systems (Nanoplasty and Percuplasty) and the SpeedMTP fusion system. The company operates primarily in the United States through a direct sales force and independent agencies.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 Value | 2024 Value |
|---|---|---|
| Revenue | $212.7 million | $209.4 million |
| Gross Profit | $169.8 million | $168.3 million |
| Gross Margin | 79.8% | 80.4% |
| Net Loss | ($59.0) million | ($55.7) million |
| Operating Loss | ($54.2) million | ($55.7) million |
| Cash & Cash Equivalents | $10.7 million | $11.4 million |
| Marketable Securities | $37.7 million | $64.3 million |
| Total Debt (Principal) | $60.0 million | $54.0 million |
| Accumulated Deficit | ($249.0) million | ($190.0) million |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased by 1.6% ($3.3 million) driven by higher procedure kit volumes, partially offset by lower average selling prices of new products and macroeconomic headwinds affecting elective surgery demand.
- Margin Compression: Gross margin decreased to 79.8% from 80.4%, primarily due to lower-margin sales to stocking distributors (which accounted for $13.0 million in revenue) and increased inventory provisions ($1.1 million increase).
- Expense Management: Sales and marketing expenses decreased by 4.6% ($6.8 million) due to an $8.2 million reduction in direct-to-consumer advertising and optimization of the sales force. However, General and Administrative expenses increased by 12.6% ($7.0 million), largely driven by a $5.4 million increase in legal fees related to ongoing patent litigation.
- Debt Refinancing: In Q4 2025, the company refinanced its previous MidCap facilities with a new $175.0 million senior secured loan arrangement (SLR), borrowing $60.0 million initially. This resulted in a $2.7 million debt extinguishment loss.
- Active Surgeons: The number of active surgeons increased by 6% to 3,337.
Guidance, Outlook, and Risks
Outlook & Strategy: Management plans to reduce direct-to-patient marketing spending in 2026 to improve profitability. The company is transitioning from a single-product focus to a comprehensive bunion solutions provider, with upcoming launches in 2026 including the Lapiplasty Lightning instrumentation and SpeedTMT implants. Management believes existing cash, marketable securities, and debt facilities are sufficient to fund operations for at least the next 12 months.
Key Risks & Contingencies:
- Profitability: The company has incurred net losses since inception and may be unable to achieve or sustain profitability. Revenue growth has slowed, and the company faces pressure to right-size expenses.
- Competition & Product Mix: The flagship Lapiplasty System faces declining sales due to surgeon preference shifts toward minimally invasive osteotomies and competition. New products sell at lower average prices, creating margin pressure.
- Intellectual Property Litigation: The company is engaged in significant patent litigation. It is a plaintiff against Stryker and Zimmer Biomet/Paragon 28 regarding Lapiplasty patents. Conversely, it is defending against infringement suits from Stryker (hammertoe product) and Paragon 28/Disior (trade secrets/software). Outcomes are uncertain and could materially impact operations.
- Securities Litigation: A shareholder class action lawsuit was filed in April 2025 alleging violations of federal securities laws regarding undisclosed competitive impacts and product plans. The company intends to defend vigorously.
- Debt Covenants: The new loan agreements include minimum liquidity and revenue covenants. Failure to meet these could result in default and acceleration of debt.
Investor Verification Checklist
- Verify the sustainability of revenue growth given the 1.6% increase and the shift to lower-priced minimally invasive products.
- Monitor the status and potential financial impact of the ongoing patent lawsuits against Stryker and Zimmer Biomet, as well as the countersuits filed against Treace.
- Assess the company's ability to meet the minimum liquidity and revenue covenants under the new SLR credit facility.
- Review the trajectory of gross margins as the mix of sales shifts further toward stocking distributors and new, lower-priced product lines.
- Confirm the timeline and commercial success of the 2026 product launches (Lapiplasty Lightning, SpeedTMT) intended to offset Lapiplasty volume declines.